tbuckley/cabot-search huggingface dataset:
OC-020 Is Taking Histological Biopsies in Patients With Gastritis A Waste of Time and Money?
Authors: L Dawson, J Baker, K Ala, J Shutt, J Jupp, S Bridger
Journal: Gut (2016)

<h3>Introduction</h3> The clinical usefulness of taking gastric biopsies in patients with endoscopic gastritis is unclear. There are international recommendations in support of this but the cost effectiveness is questionable and there is little evidence that biopsies influence patient management.<sup>1</sup> <h3>Methods</h3> In 2014, 1109 patients were identified as having endoscopic gastritis based on a retrospective review of the hospital’s Endoscopy database. Of these patients, 610 had a urease test, 90 had both urease testing and gastric histology, 378 just had histology and 31 had neither test. A more detailed review of the patient’s clinical notes and histology was undertaken for 114 consecutive gastritis patients who had gastric biopsies sent for histological analysis over a 3 month period (Aug-Oct). <h3>Results</h3> 56% of the patients were female (64/114) with an average age of 65 years (range 17–91). 76% of these patients were taking a PPI at the time of endoscopy. Dyspepsia/reflux (43%) was the commonest primary indication, followed by anaemia/GI bleeding (24.5%), dysphagia (10.5%), nausea/vomiting (6%) and miscellaneous others. 88.5% of patients had at least 2 antral biopsies taken. 17.5% of patients had both antral and corpus biopsies. 6% of patients had both urease testing and histology. No serious pathology was found on any of the histological samples. The commonest histological diagnosis was chemical, reactive or inflammatory gastritis (70%), followed by normal (17%), <i>Helicobacter pylori</i> (Hp) gastritis (10.5%), intestinal metaplasia (1%) and fundic gland polyp (1%). <h3>Conclusion</h3> Despite recommendations to the contrary,<sup>1</sup> we found 42% of patients with uncomplicated gastritis still have gastric biopsies sent for histopathological analysis. The reasons why an Endoscopist chooses to request histology rather than a urease test are not clear. We suspect decision-making is influenced by whether the patient is taking a PPI with a perception that this may reduce the sensitivity of urease testing. However the manufacturer of Endosc-Hp™ reports a sensitivity of 94.4% in detecting Hp even if the patient is taking a PPI (email comm). Consequently there would seem to be no additional value in sending histology in this group of patients. The cost savings are considerable. Even in a DGH serving a population of 220,000, the annual cost savings of carrying out urease testing rather than histology in patients with uncomplicated gastritis would amount to at least £37000. This study supports the Royal College of Pathologists contention that “biopsy for histological classification of gastritis is unlikely to change management” and taking biopsies for patients with uncomplicated gastritis “is not recommended.”<sup>1</sup> <h3>Reference</h3> 1 Loughrey MB, Johnston BT. <i>Frontline Gastroenterology</i> 2014;<b>5</b>:88–95. <h3>Disclosure of Interest</h3> None Declared
Comparison of Quality of Life Outcomes and Psychosocial Functioning Between Patients Undergoing Myeloablative or Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Myeloid Malignancies
Authors: Aleksandr Lazaryan, Betty K. Hamilton, Linda McLellan, Lisa Rybicki, Larry Foster, Michele Cooper, Jane Dabney, Shawnda Tench, Ronald Sobecks, Hien Duong, Matt Kalaycio, Brian J. Bolwell, Edward A. Copelan
Journal: Blood (2011)
AML1-ETO9a Correlated with C-KIT Overexpression/Mutation and Indicated Poor Disease Outcome in t(8;21) Acute Myeloid Leukemia.
Authors: Yang Liang, Bo Jiao, Chuan-Feng Wu, Shu-Min Xiong, Long-Jun Gu, Zhu Chen, Sai-Juan Chen
Journal: Blood (2007)
AB0568 Giant Cell Arteritis and Malignancy – More than Just A Coincidence?
Authors: R. Ješe, A. Hočevar, Ž. Rotar, S. Praprotnik, M. Tomšič
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Malignancy associated vasculitis represents 2–5% of systemic vasculitides. While there have been reports of increased incidence of malignancy in patients with giant cell arteritis (GCA) no definite association has yet been established. <h3>Objectives</h3> To determine the proportion patients with GCA and past/concurrent/subsequent malignancy. <h3>Methods</h3> We conducted a prospective longitudinal analysis of patients diagnosed with GCA from September 2011 to December 2015 at a single secondary/tertiary rheumatology centre. The proportion of patients with past, concurrent, and successive malignancy (diagnosed within 1 year of follow-up) was determined. Crude incidence rate (CIR) of malignancy in general population aged 50 years and above from the same geographical region in year 2011 and 2012 (final accessible reports based on complete yearly data) was acquired from Slovenian Cancer Registry for comparison. <h3>Results</h3> During the observation period 106 new GCA cases were identified (Table 1). Nineteen patients (17.9%) were diagnosed with a malignancy at any point in time (Table 2). In 7 patients (6.6%) malignant disease was found concomitantly with GCA (4/7) or within one year of follow-up (3/7). With respect to location of these 7 newly diagnosed malignancies, there were 4 cases (3.8%) of urinary bladder cancer (Table 2). There was 1 death due to cancer during the follow-up. None of the 12 patients with a history of past malignant disease had a recurrence of cancer at GCA diagnosis or during the follow-up. CIR for malignancy in comparably aged population of the same geographical region was 1.51%, with cumulative CIR for urinary tract malignancy of 0.08% and specific CIR for bladder cancer of 0.04%. <h3>Conclusions</h3> In our study, 6.6% of GCA patients were found to have a concurrent malignant disease compared to 1.5% of similarly aged general population. Additionally, we detected an increased incidence of urinary bladder cancer in our GCA cohort. <h3>Disclosure of Interest</h3> None declared
Comparison of Single Agent GA101 In Japanese and European Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL) – Results From Two Phase I Studies
Authors: Michinori Ogura, Franck Morschhauser, Kensei Tobinai, Guillaume Cartron, Kiyohiko Hatake, Michael K. Wenger, Joe Birkett, Naoko Oya, Kiyomi Nishima, Gilles Salles
Journal: Blood (2010)
SP0074 What Is New: Early Arthritis
Authors: K. Raza
Journal: Annals of the Rheumatic Diseases (2016)

New onset inflammatory sounding joint pain (or clinically suspect arthralgia) and new onset inflammatory arthritis are both common. In some cases patients develop rheumatoid arthritis (RA) and in others symptoms and signs resolve spontaneously. This WIN session will highlight important recent developments in the areas of (a) disease mechanisms, (b) outcome prediction, (c) care pathways and (d) therapeutic approaches, for patients with, or at risk of, new onset synovial swelling. <h3>Disclosure of Interest</h3> None declared
AB0730 Psoriatic Arthritis Patients with Work Disability Have Worse Quality of Life Compared To Those Who Are Employed
Authors: F. Farkas, A. Szentpetery, P. Gallagher, O. FitzGerald
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Work disability (WD) is an important functional outcome measure in inflammatory arthritis, which has been studied comprehensively in rheumatoid arthritis and ankylosing spondylitis, however limited data is available in psoriatic arthritis (PsA). A variety of WD measurement tools are available, but there are no validated and specific guidelines in PsA [1,2]. <h3>Objectives</h3> In PsA patients with and without WD: (1) to compare patient-reported outcomes (PROs) and physician-assessed measures and (2) to assess whether there are gender-specific differences associated with WD. <h3>Methods</h3> Consecutive patients with PsA fulfilling the CASPAR criteria were enrolled. Patients on disability pension, those with early retirement due to arthritis, those unemployed, away from work due to sick leave were considered as having WD. Disease activity measures (TJC/68, SJC/66, ESR, CRP, PASI), economic data, patient-reported outcome measures (HAQ, EQ-5D, SF-36, BASDAI, BASFI, ASQoL, DLQI, pain VAS, average level of fatigue), radiographic damage, medication history and comorbidities were compared between employed and work-disabled patients in both genders using Mann-Whitney pairwise and chi-square test. <h3>Results</h3> 81 patients completed the economic questionnaire. Thirty-eight (17 male and 21 female) participations of working age had work disability versus forty-three (20 male, 23 female) employed patients. Out of 81 patients, 27 were biologic-naïve and 54 had ever been on biologic agents. We have found no significant differences in disease activity measures or in the number of erosions between work-disabled and employed patients. On the other hand patients with WD had significantly worse self-reported values in both gender groups, especially in females. The total number of comorbidities (p=0.020) and coexistent rheumatic diseases (p=0.025) were significantly higher among patients with WD. Work-disabled patients had more healthcare-related appointments and required more help (p=0.001), including home care and assistance travelling to the hospital. <h3>Conclusions</h3> Consistent with previous studies, in this cross-sectional cohort we have observed that rates of WD are high (46.9%) among patients with PsA with no difference between males and females. Despite similar disease activity and structural damage measures, patients with WD had worse physical function and overall reduced quality of life compared to employed patients. These differences were more pronounced in females, who had more physical and social limitations related to PsA. <h3>References</h3> Tillett, W., C. de-Vries, and N.J. McHugh, Work disability in psoriatic arthritis: a systematic review. Rheumatology, 2012. 51(2): p. 275–283. Wallenius, M., et al., Work disability and health-related quality of life in males and females with psoriatic arthritis. Ann Rheum Dis, 2009. 68(5): p. 685–9. <h3>Disclosure of Interest</h3> None declared
AB0665 Impact of Disease Activity on Psychological Status in Patients with Spondyloarthritis
Authors: A. Ben Tekaya, I. Mahmoud, R. Tekaya, O. Saidane, L. Abdelmoula
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a standard instrument regularly used to assess disease activity of patients with spondyloarthritis (SpA). However, the well-being of a patient is also affected by impairment of function as well as psychological status especially depression and anxiety. <h3>Objectives</h3> The aim of this study was to investigate the relationship between disease activity measured by the BASDAI and psychological variables. <h3>Methods</h3> This was a cross-sectional study at a rheumatology department over a twelve months period. Patients with diagnosis of SpA (ASAS 2009) were recruited. Respectively, disease status and psychological status were assessed by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Hospital Anxiety and Depression Scale (HADS). A statistical analysis was performed. <h3>Results</h3> A total of 100 patients were enrolled; mostly male (71%). The mean age of the sample was 41,72 (±13,57) years; the mean disease duration at study baseline was 11,87 (±10,3) years. Mean morning stiffness 30,26 minutes. The mean score on VAS pain was 60,3mm (±28,66). At baseline, the mean BASDAI score was 4,5 (±2,3); 57% have BASDAI greater than or equal to 4. The mean (SD) scores by the study participants on the HADS-Anxiety (HASD-A) and HADS-Depression (HADS-D) were 8,9 (±5,08) and 7,23 (±5,27), respectively. The prevalence of anxious symptomatology based on the HADS-A was 39%, 18% were classified as possible anxiety cases. Based on HADS-D scores, 31% of the patients presented symptoms of depression and 15% possible depression. BASDAI was positively correlated with both HADS-D (r=0.505, p&lt;0.0001) and HADS-A (r=0.425, p&lt;0.0001). The multivariate logistic regression analysis revealed that patients9 whose BASDAI&gt;4 at baseline was an independent risk factor associated with the risk of both depression (OR=4.9, 95%CI [1.7–13.9], p=0.002) and anxiety (OR=2.7, 95%CI [1.1–6.7], p=0.027). <h3>Conclusions</h3> This study underscore that high disease activity increased significantly the risk of depression and anxiety in SpA. <h3>Disclosure of Interest</h3> None declared
TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding
Authors: Penka S. Petrova, Natasja Nielsen Viller, Mark Wong, Xinli Pang, Gloria H.Y. Lin, Karen Dodge, Vien Chai, Hui Chen, Vivian Lee, Violetta House, Noel T. Vigo, Debbie Jin, Tapfuma Mutukura, Marilyse Charbonneau, Tran Truong, Stephane Viau, Lisa D. Johnson, Emma Linderoth, Eric L. Sievers, Saman Maleki Vareki, Rene Figueredo, Macarena Pampillo, James Koropatnick, Suzanne Trudel, Nathan Mbong, Liqing Jin, Jean C.Y. Wang, Robert A. Uger
Journal: Clinical Cancer Research (2016)

Purpose: The ubiquitously expressed transmembrane glycoprotein CD47 delivers an anti-phagocytic (do not eat) signal by binding signal-regulatory protein α (SIRPα) on macrophages. CD47 is overexpressed in cancer cells and its expression is associated with poor clinical outcomes. TTI-621 (SIRPαFc) is a fully human recombinant fusion protein that blocks the CD47-SIRPα axis by binding to human CD47 and enhancing phagocytosis of malignant cells. Blockade of this inhibitory axis using TTI-621 has emerged as a promising therapeutic strategy to promote tumor cell eradication.Experimental Design: The ability of TTI-621 to promote macrophage-mediated phagocytosis of human tumor cells was assessed using both confocal microscopy and flow cytometry. In vivo antitumor efficacy was evaluated in xenograft and syngeneic models and the role of the Fc region in antitumor activity was evaluated using SIRPαFc constructs with different Fc tails.Results: TTI-621 enhanced macrophage-mediated phagocytosis of both hematologic and solid tumor cells, while sparing normal cells. In vivo, TTI-621 effectively controlled the growth of aggressive AML and B lymphoma xenografts and was efficacious in a syngeneic B lymphoma model. The IgG1 Fc tail of TTI-621 plays a critical role in its antitumor activity, presumably by engaging activating Fcγ receptors on macrophages. Finally, TTI-621 exhibits minimal binding to human erythrocytes, thereby differentiating it from CD47 blocking antibodies.Conclusions: These data indicate that TTI-621 is active across a broad range of human tumors. These results further establish CD47 as a critical regulator of innate immune surveillance and form the basis for clinical development of TTI-621 in multiple oncology indications. Clin Cancer Res; 23(4); 1068-79. ©2016 AACR.
Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy
Authors: C. Michael Gibson, Duane S. Pinto, Gerald Chi, Douglas Arbetter, Megan Yee, Roxana Mehran, Christoph Bode, Jonathan Halperin, Freek W.A. Verheugt, Peter Wildgoose, Paul Burton, Martin van Eickels, Serge Korjian, Yazan Daaboul, Purva Jain, Gregory Y.H. Lip, Marc Cohen, Eric D. Peterson, Keith A.A. Fox
Journal: Circulation (2016)

Patients with atrial fibrillation who undergo intracoronary stenting traditionally are treated with a vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT), yet this treatment leads to high risks of bleeding. We hypothesized that a regimen of rivaroxaban plus a P2Y12 inhibitor monotherapy or rivaroxaban plus DAPT could reduce bleeding and thereby have a favorable impact on all-cause mortality and the need for rehospitalization.Stented subjects with nonvalvular atrial fibrillation (n=2124) were randomized 1:1:1 to administration of reduced-dose rivaroxaban 15 mg daily plus a P2Y12 inhibitor for 12 months (group 1); rivaroxaban 2.5 mg twice daily with stratification to a prespecified duration of DAPT of 1, 6, or 12 months (group 2); or the reference arm of dose-adjusted VKA daily with a similar DAPT stratification (group 3). The present post hoc analysis assessed the end point of all-cause mortality or recurrent hospitalization for an adverse event, which was further classified as the result of bleeding, a cardiovascular cause, or another cause blinded to treatment assignment.The risk of all-cause mortality or recurrent hospitalization was 34.9% in group 1 (hazard ratio=0.79; 95% confidence interval, 0.66-0.94; P=0.008 versus group 3; number needed to treat=15), 31.9% in group 2 (hazard ratio=0.75; 95% confidence interval, 0.62-0.90; P=0.002 versus group 3; number needed to treat=10), and 41.9% in group 3 (VKA+DAPT). Both all-cause death plus hospitalization potentially resulting from bleeding (group 1=8.6% [P=0.032 versus group 3], group 2=8.0% [P=0.012 versus group 3], and group 3=12.4%) and all-cause death plus rehospitalization potentially resulting from a cardiovascular cause (group 1=21.4% [P=0.001 versus group 3], group 2=21.7% [P=0.011 versus group 3], and group 3=29.3%) were reduced in the rivaroxaban arms compared with the VKA arm, but other forms of rehospitalization were not.Among patients with atrial fibrillation undergoing intracoronary stenting, administration of either rivaroxaban 15 mg daily plus P2Y12 inhibitor monotherapy or 2.5 mg rivaroxaban twice daily plus DAPT was associated with a reduced risk of all-cause mortality or recurrent hospitalization for adverse events compared with standard-of-care VKA plus DAPT.URL: http://www.clinicaltrials.gov. Unique identifier: NCT01830543.
Human Leukocyte Antigen (HLA) DR15 Is Associated with Reduced Incidence of Acute GvHD in HLA-Matched Allogeneic HSCT but Does Not Impact Survival.
Authors: Minoo Battiwalla, Theresa Hahn, Hilary N. Roy, Afrin Wahab, Eileen A. Duman, Joanne Becker, Philip L. McCarthy
Journal: Blood (2004)
Multimodality therapy for pulmonary metastasis in sarcoma patients: Results of a single institution.
Authors: Nasreen A. Vohra, Shawn Tejiram, Christy Yoon-Hee Chai, Anthony Paul Conley, Damon R. Reed, Eric M. Toloza, Jacques Fontaine, Marilyn M Bui, David Cheong, Douglas D Letson, Jongphil Kim, Ricardo Jorge Gonzalez
Journal: Journal of Clinical Oncology (2012)

10070 Background: Pulmonary metastasectomy (PM) for sarcoma can result in significant long term survival in carefully selected patients (pts). We report our experience with pulmonary metastasectomy. Methods: After IRB approval, 120 pts who underwent PM for sarcoma at Moffitt Cancer Center from 1999 to 2011 were reviewed. Survival was calculated according to the Kaplan-Meier method with Cox proportional hazard univariate (UV) and multivariate (MV) models used to analyze relationships between clinicopathologic variables and overall survival (OS). P-value &lt; 0.05 was considered significant. Results: Median age was 51 yrs, 95(79%) pts had soft tissue sarcomas with pleomorphic being most common. Of the 25(21%) osseous sarcomas, osteosarcoma was most common. 20(15%) had synchronous metastasis (mets); of the pts with local disease only, median time to recurrence from primary resection was 13 months (mo). OS from initial resection was 55 mo for pts with local disease only vs. 27 mo for pts with synchronous mets. On UV analysis, use of radiation, number of index lesions, presence of synchronous mets and time to recurrence achieved significance. On MV analysis, only shorter time to recurrence (p=.03) and presence of synchronous mets (p=.04) were independent predictors of poor survival. 63(52%) pts [26(22%) neoadjuvant, 19(16%) adjuvant, 18(15%) both] received chemotherapy for the primary tumor, while 57(48%) did not. There was a trend towards poor survival in pts receiving chemotherapy compared to pts receiving no chemotherapy (p=0.06, HR 1.59). In addition 40(34%) pts received chemotherapy prior to PM with no difference in OS compared to pts who did not get chemotherapy (p=0.1, HR 1.55). 71(59%) had 1 PM, 32(27%) had 2 and 17(14%) had 3 or more PM with OS being 17 mo, 37 mo and 34 mo in each group, respectively. A higher number of PM was associated with improved survival (p=.01). Conclusions: Pts with a shorter disease free interval have a decreased OS as do pts with synchronous mets. Pts undergoing multiple PM have a survival benefit likely resulting from favorable disease biology. Failure of chemotherapy to show a survival benefit may be a result of selection bias for patients with aggressive disease being treated with chemotherapy.
AB0601 Significant Cardiological Changes in Systemic Sclerosis: An Electrocardiographic and Echocardiographic Evaluation: Table 1.
Authors: I. Sciarra, D. D'Aluisio, G. Onelli, M. Vasile, K. Stefanantoni, S. Morelli, G. Valesini, V. Riccieri
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Cardiac involvement in Systemic Sclerosis (SSc) is rather common and it can be considered a bad prognostic feature. <h3>Objectives</h3> In this study we aimed to evaluate this involvement performing electrocardiogram (ECG) and echocardiogram in a group of SSc patients, comparing their data with those of healthy volunteers (NC). <h3>Methods</h3> Seventy-one consecutive SSc patients (Group A) were compared to 60 NC (Group B), matched for age and sex. Both patients and NC were evaluated by anamnesis, physical examination, ECG and trans-thoracic echocardiogram, with Doppler and tissue-wave Doppler. <h3>Results</h3> Ten SSc patients and 3 NC were excluded (Group A: 4 patients for increased basal heart rate, 2 for TAPSE &lt;17 mm, 3 for valvular disease and 1 patient for severe pulmonary hypertension. Group B: 3 subjects for high basal heart rate). Among SSc patients 22 (36.1%) had a diffuse cutaneous form (dcSSc), and 39 (73.9%) had a limited cutaneous form (lcSSc). In table 1 clinical-demographic and laboratory features of patients are described. QT dispersion (QTd) and QTc dispersion (QTcd) were significantly higher in Group A respect to Group B (QTd 49.83 vs 27.85 msec, p&lt;0.0001; QTcd: 51.39 vs 29.73 msec, p&lt;0.0001). Patients with dcSSc showed longer QTc values than controls (440.58±18.23 vs 427.64±23.12 msec, p=0.02). Left ventricular mass index (LVMI) mean values were significantly increased while left ventricular ejection fraction (LVEF) mean values were significantly reduced in Group A compared with Group B respectively (LVMI: 80.5 vs 61.54 g/m<sup>2</sup>, p&lt;0.0001; LVEF: 63.55 vs 68.42%, p=0.0001). No patient with LVEF&lt;55% was found. In addition left atrial volume index for body surface (LAVI) mean values were higher in Group A (27.67 vs 18.78 ml/m<sup>2</sup>, p&lt;0.0001). The percentage of patients with left ventricular diastolic dysfunction (LVDD) was higher in Group A (70.5 vs 21.8%, p=0.0001). In Group A QTc prolungation, increased levels of QTcd and P wave duration were associated with LVDD. An increase of P-wave duration was also associated with higher values of LAVI (p=0.04). <h3>Conclusions</h3> Significant cardiological differences can be found in SSc, even in asymptomatic patients, respect to NC, thus confirming how ECG and echocardiogram are relevant instruments able to detect morpho-functional abnormalities suggestive of an early myocardial involvement in this disease. <h3>Disclosure of Interest</h3> None declared
Inhibition of Multiple Myeloma Tumor Growth and FGFR3 by the Aurora-Angiogenesis Inhibitor ENMD-981693.
Authors: Todd A. Hembrough, Xiaoru Chen, Patricia A. Burke, Glenn M. Swartz, Kathleen Bengali, Richard Brokx, Theresa M. LaVallee, Mark R. Bray
Journal: Blood (2007)
Ribavirin-Induced Intracellular GTP Depletion Upregulates Factor VII Expression
Authors: Atsuo Suzuki, Yuhri Miyawaki, Eriko Okuyama, Moe Murata, Ando Yumi, Io Kato, Yuki Takagi, Akira Takagi, Takashi Murate, Hidehiko Saito, Tetsuhito Kojima
Journal: Blood (2012)
The PP2A Subunit B55α Suppresses Survival Signaling in Acute Myeloid Leukemia Cells
Authors: Peter P. Ruvolo, Vivian Ruvolo, Zhihong Zeng, YiHua Qui, Liran Zhou, Kelly E Gallagher, Marina Konopleva, Steven M. Kornblau, Michael Andreeff
Journal: Blood (2011)